Webinar

The First 5 Months: Practical Implications of the JCA

In this learning session, “The First 5 Months: Practical Implications of the JCA,” our expert discusses the early experiences and insights gained from the implementation of the Joint Clinical Assessment (JCA) under the EU HTA regulation. Ann-Sophie Kuschel shares practical implications for stakeholders involved in the development and commercialization of cell and gene therapies, highlighting the unique challenges and considerations relevant to this process. 

Explore and how the JCA impacts the landscape for advanced therapies in Europe to prepare to navigate this evolving regulatory environment. 

Speaker: 

  • Ann-Sophie Kuschel - Principal at Vintura, a Cencora company 

Fill out the form to watch the session

Pardot Form

Connect with our cell and gene experts

Schedule some time with our cell and gene experts today. We look forward to hearing from you.
Abstract

Related resources

Article

From AI to regulatory layering and convergence: Key takeaways from RAPS Euro Convergence 2026

Article

How U.S. pricing reform is reshaping global market dynamics

Guide

Cell and gene therapy playbook for payer engagement: Translating payer expectations into actionable market access strategies